Basilea reported good momentum in H120 as total revenues increased to CHF69.3m (+9.7%), highlighting ongoing growth in Cresemba (severe mould infections) sales. Basilea has retained FY20 guidance for revenue and its updated guidance for operating loss (CHF5–15m vs prior expected loss of CHF20–30m) reflects the one-time gain (c CHF15m) related to the sale of its headquarters. We expect H220 to be event-driven, with multiple R&D-related inflection points (derazantinib data in iC
19 Aug 2020
Basilea Pharmaceutica - A tale of two halves
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Basilea Pharmaceutica - A tale of two halves
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
19 Aug 2020 -
Author:
Dr Susie Jana -
Pages:
8
Basilea reported good momentum in H120 as total revenues increased to CHF69.3m (+9.7%), highlighting ongoing growth in Cresemba (severe mould infections) sales. Basilea has retained FY20 guidance for revenue and its updated guidance for operating loss (CHF5–15m vs prior expected loss of CHF20–30m) reflects the one-time gain (c CHF15m) related to the sale of its headquarters. We expect H220 to be event-driven, with multiple R&D-related inflection points (derazantinib data in iC